Panoplies des therapies ciblees par anticorps monoclonaux en dermatologie. Actualite et prospectives.

Targeted therapies are focused on one or a few molecules particularly involved in specific diseases. Some inflammatory dermatoses and cutaneous neoplasia potentially benefit from these approaches. Nine monoclonal antibodies of interest in dermatology are presented according to the disorders where they have proven their efficacy. Biotherapies extend beyond monoclonal antibodies. A given effect, such as TNF-alpha antagonism, is indeed obtained by distinct drug classes. The interindividual differences in the therapeutic responses remain unpredictable, and there is no criteria of selection of patients who could benefit the most from these targeted medications.